For example, TNFα-, IL-6R- and IL-1β-neutralizing bDMARDs work in RA, whereas IL-17A and IL-12/23-neutralizing bDMARDs are very efficient in psoriatic arthritis or spondyloarthritis. This evidence concerns the gene IL17A and spondyloarthropathy.